SBTX.L
SkinBioTherapeutics Plc [SBTX.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SBTX.L Stock Summary
Top 10 Correlated ETFs
SBTX.L
Top 10 Correlated Stocks
SBTX.L
In the News
SBTX.L Financial details
Company Rating
Neutral
Market Cap
19.54M
Income
-5.89M
Revenue
291.45K
Book val./share
0.02
Cash/share
0.02
Dividend
-
Dividend %
-
Employees
11
Optionable
No
Shortable
Yes
Earnings
26 Mar 2024
P/E
-19.22
Forward P/E
-
PEG
-1.91
P/S
389.45
P/B
12.38
P/C
472
P/FCF
-30.17
Quick Ratio
2.48
Current Ratio
3.25
Debt / Equity
0.01
LT Debt / Equity
-
-
-
EPS (TTM)
-0.04
EPS next Y
-
EPS next Q
-
EPS this Y
-3.37%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
93.52%
EPS Q/Q
-16.67%
-
-
-
-
SMA20
25%
SMA50
-9.09%
SMA100
-50%
Inst Own
-
Inst Trans
-
ROA
-50%
ROE
80%
ROC
-0.65%
Gross Margin
67%
Oper. Margin
-1755%
Profit Margin
-1669%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
7.0-29.5
52W High
-67.45%
52W Low
+34.86%
RSI
48
Rel Volume
0.07
Avg Volume
810.29K
Volume
57.27K
Perf Week
-3.18%
Perf Month
14.42%
Perf Quarter
-66.29%
Perf Half Y
-58.04%
-
-
-
-
Beta
1.613
-
-
Volatility
0.21%, 1.46%
Prev Close
1.29%
Price
9.44
Change
-1.67%
SBTX.L Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-06-30
| Metric | History | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 | |
| Operating cash flow per share | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 | |
| Free cash flow per share | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 | |
| Cash per share | 0.03 | 0.02 | 0.03 | 0.01 | 0.01 | |
| Book value per share | 0.03 | 0.02 | 0.04 | 0.02 | 0.01 | |
| Tangible book value per share | 0.03 | 0.02 | 0.03 | 0.01 | 0.01 | |
| Share holders equity per share | 0.03 | 0.02 | 0.04 | 0.02 | 0.01 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 24.41M | 21.93M | 93.15M | 31.75M | 20.59M | |
| Enterprise value | 21.28M | 19.78M | 88.68M | 30.07M | 19.38M | |
| P/E ratio | -21.26 | -14.62 | -65.01 | -11.37 | -7.26 | |
| Price to sales ratio | 0 | 0 | 0 | 424.66 | 155.91 | |
| POCF ratio | -17.09 | -24.59 | -59.9 | -11.88 | -7.78 | |
| PFCF ratio | -16.96 | -22.71 | -55.87 | -11.46 | -7.33 | |
| P/B Ratio | 6.41 | 8.9 | 17.86 | 12.83 | 10.32 | |
| PTB ratio | 6.41 | 8.9 | 17.86 | 12.83 | 10.32 | |
| EV to sales | 0 | 0 | 0 | 402.23 | 146.74 | |
| Enterprise value over EBITDA | -15.7 | -12.25 | -59.55 | -10.19 | -6.56 | |
| EV to operating cash flow | -14.9 | -22.17 | -57.03 | -11.25 | -7.33 | |
| EV to free cash flow | -14.79 | -20.48 | -53.19 | -10.86 | -6.9 | |
| Earnings yield | -0.05 | -0.07 | -0.02 | -0.09 | -0.14 | |
| Free cash flow yield | -0.06 | -0.04 | -0.02 | -0.09 | -0.14 | |
| Debt to equity | 0 | 0 | 0.03 | 0.05 | 0.05 | |
| Debt to assets | 0 | 0 | 0.02 | 0.04 | 0.04 | |
| Net debt to EBITDA | 2.31 | 1.34 | 3 | 0.57 | 0.41 | |
| Current ratio | 29.49 | 7.7 | 12.5 | 4.58 | 3.25 | |
| Interest coverage | 0 | 0 | -1.61K | -294.13 | -337.54 | |
| Income quality | 1.24 | 0.59 | 1.09 | 0.96 | 0.93 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0.38 | 0.28 | |
| Research and developement to revenue | 0 | 0 | 0 | 11.52 | 7.05 | |
| Intangibles to total assets | 0.09 | 0.15 | 0.09 | 0.2 | 0.27 | |
| Capex to operating cash flow | 0.01 | 0.08 | 0.07 | 0.04 | 0.06 | |
| Capex to revenue | 0 | 0 | 0 | -1.29 | -1.25 | |
| Capex to depreciation | -3 | -14.44 | -22.22 | -3.26 | -3.74 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0.7 | 0.01 | |
| Graham number | 0.08 | 0.07 | 0.09 | 0.08 | 0.07 | |
| ROIC | -0.3 | -0.61 | -0.26 | -1.03 | -1.31 | |
| Return on tangible assets | -0.32 | -0.64 | -0.28 | -1.14 | -1.5 | |
| Graham Net | 0.03 | 0.02 | 0.03 | 0.01 | 0.01 | |
| Working capital | 3.46M | 2.04M | 4.66M | 1.82M | 1.19M | |
| Tangible asset value | 3.46M | 2.05M | 4.69M | 1.85M | 1.29M | |
| Net current asset value | 3.46M | 2.04M | 4.54M | 1.72M | 1.12M | |
| Invested capital | 0 | 0 | 0.03 | 0.05 | 0.05 | |
| Average receivables | 219.18K | 213.62K | 177.4K | 270.96K | 316.63K | |
| Average payables | 94.91K | 98.93K | 108.71K | 75.73K | 133.44K | |
| Average inventory | -219.18K | -142.93K | 0 | 61.29K | 78.03K | |
| Days sales outstanding | 0 | 0 | 0 | 1.6K | 842.38 | |
| Days payables outstanding | 6.36K | 9.92K | 5.69K | 450.37 | 784.37 | |
| Days of inventory on hand | -30.69K | 0 | 0 | 760.26 | 135.24 | |
| Receivables turnover | 0 | 0 | 0 | 0.23 | 0.43 | |
| Payables turnover | 0.06 | 0.04 | 0.06 | 0.81 | 0.47 | |
| Inventory turnover | -0.01 | 0 | 0 | 0.48 | 2.7 | |
| ROE | -0.3 | -0.61 | -0.27 | -1.13 | -1.42 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q2
| Metric | History | 2021-12-31 | 2022-06-30 | 2022-12-31 | 2023-06-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | |
| Operating cash flow per share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | |
| Free cash flow per share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | |
| Cash per share | 0.02 | 0.01 | 0 | 0.01 | 0.02 | |
| Book value per share | 0.03 | 0.02 | 0.01 | 0.01 | 0.02 | |
| Tangible book value per share | 0.02 | 0.01 | 0 | 0.01 | 0.02 | |
| Share holders equity per share | 0.03 | 0.02 | 0.01 | 0.01 | 0.02 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 65.85M | 31.75M | 24.3M | 21.49M | 26.97M | |
| Enterprise value | 62.82M | 30.07M | 23.64M | 20.28M | 24.23M | |
| P/E ratio | -15.31 | -4.62 | -4.73 | -3.47 | -5.05 | |
| Price to sales ratio | 3K | 601.15 | 315.66 | 390.23 | 253.1 | |
| POCF ratio | -46.95 | -24.99 | -24.45 | -13.02 | -19.75 | |
| PFCF ratio | -45.6 | -23.94 | -23.8 | -12.01 | -18.71 | |
| P/B Ratio | 15.82 | 12.83 | 20.04 | 10.77 | 7.39 | |
| PTB ratio | 15.82 | 12.83 | 20.04 | 10.77 | 7.39 | |
| EV to sales | 2.86K | 569.4 | 307.13 | 368.23 | 227.36 | |
| Enterprise value over EBITDA | -54.92 | -16.63 | -17.71 | -12.51 | -18.07 | |
| EV to operating cash flow | -44.79 | -23.67 | -23.79 | -12.28 | -17.75 | |
| EV to free cash flow | -43.51 | -22.68 | -23.16 | -11.33 | -16.8 | |
| Earnings yield | -0.02 | -0.05 | -0.05 | -0.07 | -0.05 | |
| Free cash flow yield | -0.02 | -0.04 | -0.04 | -0.08 | -0.05 | |
| Debt to equity | 0.03 | 0.05 | 0.09 | 0.05 | 0.01 | |
| Debt to assets | 0.03 | 0.04 | 0.06 | 0.04 | 0.01 | |
| Net debt to EBITDA | 2.65 | 0.93 | 0.49 | 0.75 | 2.05 | |
| Current ratio | 11.19 | 4.58 | 1.77 | 3.25 | 6.57 | |
| Interest coverage | -219.65 | -375.15 | -285.1 | -397.46 | -361.37 | |
| Income quality | 1.3 | 0.74 | 0.77 | 1.07 | 1.02 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 34.18 | 25.42 | 11.71 | 20.46 | 0 | |
| Research and developement to revenue | 18.07 | 8.8 | 5.77 | 8.83 | 2.33 | |
| Intangibles to total assets | 0.12 | 0.2 | 0.33 | 0.27 | 0 | |
| Capex to operating cash flow | 0.03 | 0.04 | 0.03 | 0.08 | 0.06 | |
| Capex to revenue | -1.89 | -1.05 | -0.35 | -2.51 | -0.72 | |
| Capex to depreciation | -2.85 | -3.66 | -1.66 | -4.96 | -1.7 | |
| Stock based compensation to revenue | 0.97 | 0.59 | 0.29 | -0.38 | 0 | |
| Graham number | 0.06 | 0.06 | 0.04 | 0.05 | 0.06 | |
| ROIC | -0.24 | -0.63 | -0.91 | -0.71 | -0.36 | |
| Return on tangible assets | -0.27 | -0.7 | -0.96 | -0.82 | -0.32 | |
| Graham Net | 0.02 | 0.01 | 0 | 0.01 | 0.01 | |
| Working capital | 3.56M | 1.82M | 532.09K | 1.19M | 2.79M | |
| Tangible asset value | 3.59M | 1.85M | 559.97K | 1.29M | 3.65M | |
| Net current asset value | 3.46M | 1.72M | 449.26K | 1.12M | 2.73M | |
| Invested capital | 0.03 | 0.05 | 0.09 | 0.05 | 0.01 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 1.43K | 559.79 | 433.52 | 498.07 | 339.77 | |
| Days payables outstanding | 1.26K | 1.21K | 1.44K | 907.4 | 499.54 | |
| Days of inventory on hand | 1.6K | 308.92 | 190.95 | 60.95 | 50.62 | |
| Receivables turnover | 0.06 | 0.16 | 0.21 | 0.18 | 0.26 | |
| Payables turnover | 0.07 | 0.07 | 0.06 | 0.1 | 0.18 | |
| Inventory turnover | 0.06 | 0.29 | 0.47 | 1.48 | 1.78 | |
| ROE | -0.26 | -0.69 | -1.06 | -0.78 | -0.37 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
SBTX.L Frequently Asked Questions
What is SkinBioTherapeutics Plc stock symbol ?
SkinBioTherapeutics Plc is a GB stock and trading under the symbol SBTX.L
What is SkinBioTherapeutics Plc stock quote today ?
SkinBioTherapeutics Plc stock price is $9.44 today.
Is SkinBioTherapeutics Plc stock public?
Yes, SkinBioTherapeutics Plc is a publicly traded company.
Company Profile
- Volume Average 810.29K
- Market Capitalization 19.54M
- Employee 11
- CEO Mr. Stuart John Ashman
- Headquarters Newcastle upon Tyne,GB
- IPO Date 2017-04-05
-
Website
https://www.skinbiotherapeutics.com 
SkinBioTherapeutics plc, a life science company, engages in the research and development of technology that harnesses the human microbiome to improve health. The company develops SkinBiotix technology that can enhance the barrier effect of skin models, protect skin from infections, and repair wounds; and AxisBiotix that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company has a collaboration agreement with Croda Plc; the University of Manchester to develop immune-supporting microbiome formulations; and Winclove Probiotics B.V. for the development of a probiotic blend of good bacterial strains based on the modifying properties of specific bacterial species in known psoriasis pathways. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.
